02Feb 2024
Effect of sacubitril valsartan on heart failure with mid-range or preserved EF in patients on maintenance hemodialysis

Effect of sacubitril valsartan on heart failure with mid-range or preserved EF in patients on maintenance hemodialysis

A study assessed sacubitril valsartan's impact on heart failure (HF) in hemodialysis patients with preserved ejection fraction (HFpEF). Over 12 months, 155 patients, with EF >40%, were monitored, 59 receiving SV. SV improved diastolic function and reduced left ventricular parameters but didn't significantly alter HF hospitalization or cardiovascular death rates. The Acute Dialysis Quality Initiative (ADQI) HF class improved with SV. Independent risk factors for HFpEF patients included age, diabetes, and pulmonary arterial pressure. While SV enhanced certain cardiac measures, it didn't reduce HF hospitalization or cardiovascular mortality in this population.

  • #cardiology

Like

Save

Share